Amisulpride as add-on treatment for resistant obsessive-compulsive disorder: Retrospective case series

Clinical Neuropharmacology

Volumn 38, Issue 1, 2015, Pages 26-29

  Miodownik, Chanoch ^a   Bergman, Joseph ^b   Lerner, Paul P ^c   Kreinin, Anatoly ^b   Lerner, Vladimir ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b Technion Medical School   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

Author keywords

amisulpride; antidepressants; augmentation; Obsessive compulsive disorder; treatment; treatment resistant OCD

Indexed keywords

AMISULPRIDE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIANSERIN; MIRTAZAPINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADD ON THERAPY; ADULT; AKATHISIA; ARTICLE; CASE STUDY; CLINICAL ARTICLE; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROTONINERGIC SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

EID: 84963957159     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000065     Document Type: Article

References (44)

1. Weissman MM, Bland RC, Canino GJ, et al. The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. J Clin Psychiatry 1994;55:5-10.
2. Murray CJL, Lopez AD. Global Burden of Disease: A Comprehensive Assessment of Mortality and Morbidity From Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Boston, MA: WHO; 1996.
3. Karno M, Golding JM, Sorenson SB, et al. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988;45:1094-1099.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Text Revision. Washington, DC: American Psychiatric Association; 2000.
5. MajM, Sartorius N, Okasha A, et al., eds. Obsessive-Compulsive Disorder. 2nd ed. Chichester, United Kingdom: John Wiley; 2002.
6. Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder [see comments]. Arch Gen Psychiatry 1999;56:121-127.
7. Jenike MA. Clinical practice. Obsessive-compulsive disorder. N Engl J Med 2004;350:259-265.
8. March JS, Frances A, Kahn DA, et al. The Expert Consensus Guideline Series: treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997; 58:1-72.
9. Kellner M. Drug treatment of obsessive-compulsive disorder. Dialogues Clin Neurosci 2010;12:187-197.
10. Husted DS, Shapira NA. A review of the treatment for refractory obsessive-compulsive disorder: from medicine to deep brain stimulation. CNS Spectr 2004;9:833-847.
11. Arumugham SS, Reddy JY. Augmentation strategies in obsessive-compulsive disorder. Expert Rev Neurother 2013;13:187-202; quiz 203.
12. Fineberg NA, Gale TM, Sivakumaran T. A review of antipsychotics in the treatment of obsessive compulsive disorder. J Psychopharmacol 2006;20: 97-103.
13. Gao K, Muzina D, Gajwani P, et al. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 2006;67:1327-1340.
14. McDougle CJ, GoodmanWK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993;150:647-649.
15. McDougle CJ, Price LH, GoodmanWK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991;11:175-184.
16. Kim JH, Ryu S, Nam HJ, et al. Symptom structure of antipsychotic-induced obsessive compulsive symptoms in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2012;39:75-79.
17. Kulkarni G, Narayanaswamy JC, Math SB. Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia. Indian J Pharmacol 2012;44:649-650.
18. Lemke NT, Bustillo JR. Clozapine-induced obsessive-compulsive symptoms in bipolar disorder. Am J Psychiatry 2013;170:930.
19. Paparrigopoulos T, Tzavellas E, Karaiskos D, et al. Paliperidone-induced obsessive symptoms. J Neuropsychiatry Clin Neurosci 2011;23:E46.
20. Schirmbeck F, Esslinger C, Rausch F, et al. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med 2011;41:2361-2373.
21. Ulhaq I, Abba-Aji A. Haloperidol induced obsessive compulsive symptom (OCS) in a patient with learning disability and bipolar affective disorder. BMJ Case Rep 2012; 2012. pii: bcr1120115161. doi: 10.1136/bcr.11.2011.5161.
22. Alevizos B, Lykouras L, Zervas IM, et al. Risperidone-induced obsessive-compulsive symptoms: a series of six cases. J Clin Psychopharmacol 2002;22:461-467.
23. Alevizos B, Papageorgiou C, Christodoulou GN. Obsessive-compulsive symptoms with olanzapine. Int J Neuropsychopharmacol 2004;7:375-377.
24. Englisch S, Esslinger C, Inta D, et al. Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole. Clin Neuropharmacol 2009;32:227-229.
25. Lykouras L, Alevizos B, Michalopoulou P, et al. Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:333-346.
26. Mouaffak F, Gallarda T, Bayle FJ, et al.Worsening of obsessive-compulsive symptoms after treatment with aripiprazole. J Clin Psychopharmacol 2007;27:237-238.
27. Stamouli S, Lykouras L. Quetiapine-induced obsessive-compulsive symptoms: a series of five cases. J Clin Psychopharmacol 2006;26: 396-400.
28. Blin O. A comparative review of new antipsychotics. Can J Psychiatry 1999;44:235-244.
29. Kim SW, Shin IS, Kim JM, et al. Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study. J Clin Psychopharmacol 2008;28:349-352.
30. Metin O, Yazici K, Tot S, et al. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol 2003;18:463-467.
31. Jenike MA, Rauch SL. Managing the patient with treatment-resistant obsessive compulsive disorder: current strategies. J Clin Psychiatry 1994;55:11-17.
32. Franz AP, Mariana Paim M, de Araújo RM, et al. Treating refractory obsessive-compulsive disorder: what to do when conventional treatment fails? Trends Psychiatry Psychotherapy 2013;35:24-35.
33. Papp LA. Anxiety disorders: somatic treatment. In: Sadock BJ, Sadock VJ, eds. Comprehensive Textbook of Psychiatry Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 1490-1498.
34. Iancu I, Dannon PN, Dolberg OT, et al. Treatment of obsessive-compulsive disorder: from theory to practice. In: Halbreich U, Montgomery SA, eds. Pharmacotherapy for Mood, Anxiety and Cognitive Disorders Washington, DC: American Psychiatric Press; 2000:465-478.
35. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989;46:1012-1016.
36. GoodmanWK, Price LH, Rasmussen SA, et al. The Yale-BrownObsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011.
37. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education and Welfare: Washington, DC; 1976.
38. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002;5:181-191.
39. Tolin DF, Abramowitz JS, Diefenbach GJ. Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale. J Clin Psychiatry 2005;66:1549-1557.
40. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006;11:622-632.
41. Denys D, de Geus F, van Megen HJ, et al. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004;65:1040-1048.
42. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-308.
43. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry 2008;9:248-312.
44. Ersche KD, Cumming P, Craig KJ, et al. Amisulpride-induced acute akathisia in OCD: an example of dysfunctional dopamine-serotonin interactions? J Psychopharmacol 2012;26:887-890.